Publication:
Predicting Subclinical Atherosclerosis in Low-Risk Individuals Ideal Cardiovascular Health Score and Fuster-BEWAT Score

dc.contributor.authorFernandez-Alvira, Juan Miguel
dc.contributor.authorFuster, Valentin
dc.contributor.authorPocock, Stuart
dc.contributor.authorSanz, Javier
dc.contributor.authorFernandez-Friera, Leticia
dc.contributor.authorLaclaustra, Martin
dc.contributor.authorFernandez-Jimenez, Rodrigo
dc.contributor.authorMendiguren, Jose M
dc.contributor.authorFernandez-Ortiz, Antonio
dc.contributor.authorIbáñez, Borja
dc.contributor.authorBueno, Hector
dc.contributor.funderCentro Nacional de Investigaciones Cardiovasculares Carlos III (España)
dc.contributor.funderBanco Santander
dc.contributor.funderInstituto de Salud Carlos III
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)
dc.contributor.funderMinisterio de Economía, Industria y Competitividad (España)
dc.contributor.funderFundación ProCNIC
dc.contributor.funderUnión Europea. Comisión Europea
dc.contributor.funderUnión Europea
dc.contributor.funderAmerican Heart Association
dc.contributor.funderAstraZeneca
dc.contributor.funderBristol-Myers Squibb
dc.contributor.funderJanssen Cilag
dc.contributor.funderNovartis
dc.contributor.funderBayer Healthcare Pharmaceuticals-Bayer Pharma AG
dc.contributor.funderPfizer
dc.contributor.funderFerrer
dc.contributor.funderServier
dc.contributor.funderMedscape
dc.date.accessioned2018-10-19T08:00:42Z
dc.date.available2018-10-19T08:00:42Z
dc.date.issued2017
dc.description.abstractBACKGROUND The ideal cardiovascular health score (ICHS) is recommended for use in primary prevention. Simpler tools not requiring laboratory tests, such as the Fuster-BEWAT (blood pressure [B], exercise [E], weight [W], alimentation [A], and tobacco [T]) score (FBS), are also available. OBJECTIVES The purpose of this study was to compare the effectiveness of ICHS and FBS in predicting the presence and extent of subclinical atherosclerosis. METHODS A total of 3,983 participants 40 to 54 years of age were enrolled in the PESA (Progression of Early Subclinical Atherosclerosis) cohort. Subclinical atherosclerosis was measured in right and left carotids, abdominal aorta, right and left iliofemoral arteries, and coronary arteries. Subjects were classified as having poor, intermediate, or ideal cardiovascular health based on the number of favorable ICHS or FBS. RESULTS With poor ICHS and FBS as references, individuals with ideal ICHS and FBS showed lower adjusted odds of having atherosclerotic plaques (ICHS odds ratio [OR]: 0.41; 95\% confidence interval [CI]: 0.31 to 0.55 vs. FBS OR: 0.49; 95\% CI: 0.36 to 0.66), coronary artery calcium (CACS) >= 1 (CACS OR: 0.41; 95\% CI: 0.28 to 0.60 vs. CACS OR: 0.53; 95\% CI: 0.38 to 0.74), higher number of affected territories (OR: 0.32; 95\% CI: 0.26 to 0.41 vs. OR: 0.39; 95\% CI: 0.31 to 0.50), and higher CACS level (OR: 0.40; 95\% CI: 0.28 to 0.58 vs. OR: 0.52; 95\% CI: 0.38 to 0.72). Similar levels of significantly discriminating accuracy were found for ICHS and FBS with respect to the presence of plaques (C-statistic: 0.694; 95\% CI: 0.678 to 0.711 vs. 0.692; 95\% CI: 0.676 to 0.709, respectively) and for CACS >= 1 (C-statistic: 0.782; 95\% CI: 0.765 to 0.800 vs. 0.780; 95\% CI: 0.762 to 0.798, respectively). CONCLUSIONS Both scores predict the presence and extent of subclinical atherosclerosis with similar accuracy, highlighting the value of the FBS as a simpler and more affordable score for evaluating the risk of subclinical disease. (C) 2017 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.
dc.description.peerreviewed
dc.description.sponsorshipThe PESA study was co-funded by Fundacion Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) and Banco Santander. Funding was also provided by Institute of Health Carlos III (PI15/02019) and European Regional Development Fund. CNIC is supported by the Ministry of Economy, Industry and Competitiveness and Pro CNIC Foundation; and is a Severo Ochoa Center of Excellence (SEV-2015-0505). This work is part of a project that received funding from the European Union Horizon 2020 research and innovation program under Marie Sklodowska-Curie grant 707642 and American Heart Association grant 14SFRN20490315. Dr. Bueno has received research funding from Instituto de Salud Carlos III (PIE16/00021), AstraZeneca, Bristol-Myers Squibb, Janssen, and Novartis; is a consultant for Abbott, AstraZeneca, Bayer, Bristol-Myers Squibb-Pfizer, and Novartis; and has received speakers fees and travel and attendance support from AstraZeneca, Bayer, Bristol-Myers Squibb-Pfizer, Ferrer, Novartis, Servier, and Medscape. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Matthew Budoff, MD, served as Guest Editor for this paper.
dc.format.page2463-2473
dc.format.volume70
dc.identifierISI:000415137500001
dc.identifier.citationJ Am Coll Cardiol. 2017; 70(20):2463-2473
dc.identifier.doi10.1016/j.jacc.2017.09.032
dc.identifier.e-issn1558-3597
dc.identifier.issn0735-1097
dc.identifier.journalJournal of the American College of Cardiology
dc.identifier.pubmedID29145946
dc.identifier.urihttp://hdl.handle.net/20.500.12105/6493
dc.language.isoeng
dc.publisherElsevier
dc.relation.projectIDMINECO/ICTI2013-2016/SEV-2015-0505es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/H2020/707642es_ES
dc.relation.publisherversionhttps://doi.org/10.1016/j.jacc.2017.09.032
dc.repisalud.institucionCNIC
dc.repisalud.orgCNICCNIC::Grupos de investigación::Laboratorio Traslacional para la Imagen y Terapia Cardiovascular
dc.repisalud.orgCNICCNIC::Grupos de investigación::Imagen Cardiovascular y Estudios Poblacionales
dc.repisalud.orgCNICCNIC::Grupos de investigación::Investigación Cardiovascular Traslacional Multidisciplinaria
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectCardiovascular risk
dc.subjectFuster-BEWAT score
dc.subjectIdeal cardiovascular health
dc.subjectPredictive tools
dc.subjectSubclinical atherosclerosis
dc.subjectCORONARY-ARTERY CALCIUM
dc.subjectDISEASE RISK
dc.subjectHEART
dc.subjectPROGRESSION
dc.subjectASSOCIATION
dc.subjectPREVALENCE
dc.subjectMORTALITY
dc.subjectMARKERS
dc.subjectCOHORT
dc.subjectMESA
dc.titlePredicting Subclinical Atherosclerosis in Low-Risk Individuals Ideal Cardiovascular Health Score and Fuster-BEWAT Score
dc.typejournal article
dc.type.hasVersionVoR
dspace.entity.typePublication
relation.isAuthorOfPublication0aa264de-120d-4f7f-bb1d-c7bb913a04d8
relation.isAuthorOfPublication558474d4-85be-4127-bda8-59128f707249
relation.isAuthorOfPublicationee6666ff-4064-47e5-9144-afdcc607733b
relation.isAuthorOfPublication465de6aa-7383-4ba5-b278-765f894f2c87
relation.isAuthorOfPublication4b2a0672-e9a0-4788-b256-d3170c84aab2
relation.isAuthorOfPublication72ffd8e7-5d40-4645-8bc0-91b43b65e8fb
relation.isAuthorOfPublicationa6bead57-638c-4bc1-96de-94d972aa3e2c
relation.isAuthorOfPublicationc247543c-ab71-441c-8eec-b54f56c6a1ff
relation.isAuthorOfPublication2cac8bb6-2bff-4bf6-8209-bdbd21781786
relation.isAuthorOfPublication4e417023-fc1f-41d2-8130-485f76466465
relation.isAuthorOfPublication.latestForDiscovery0aa264de-120d-4f7f-bb1d-c7bb913a04d8

Files

Original bundle

Now showing 1 - 2 of 2
Loading...
Thumbnail Image
Name:
PredictingSubclinicalAtherosclerosisInLow-Risk_2017_SUPPL.docx
Size:
159.94 KB
Format:
Microsoft Word XML
Loading...
Thumbnail Image
Name:
PredictingSubclinicalAtherosclerosisInLow-Risk_2017.pdf
Size:
470.82 KB
Format:
Adobe Portable Document Format